Open an account

BioCryst Pharmaceuticals

BCRX · NASDAQ

$7.94−$0.13 (−1.61%)TodayMarket closed ·
Prev close $8.07

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.

Employees
435
Headquarters
Durham, North Carolina
Listed
Mar 4, 1994
Sector
Health Care
Industry
Biotechnology
Website
biocryst.com

Leadership

BioCryst Pharmaceuticals executives
NameTitleSince
Nancy Hutson——
Charles Gayer—2020
Babar Ghias——
Alane Barnes——
Jill Milne——
Steven Frank——
Steven Galson——
Theresa Heggie——
Alan Levin——
Amy Mckee——
Vincent Milano——
A. Machelle Sanders——

Revenue by product and region

Fiscal year ended Dec 31, 2018: $20.65M total revenue

By product

  • Collaborative and Other Research and Development [Member]$15.74M76.2%
  • Collaborative and Other Research and Development [Member]$14.55M70.5%
  • Collaborative and Other Research and Development [Member]$12.00M58.1%
  • Royalty [Member]$6.10M29.5%
  • Collaborative and Other Research and Development [Member]$2.55M12.4%
  • Collaborative and Other Research and Development [Member]$1.18M5.7%

Similar companies

Companies in the same industry as BioCryst Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.